Lamas Ferreiro Jose Luis, Álvarez Otero Judith, González González Lucía, Novoa Lamazares Luis, Arca Blanco Alexandra, Bermúdez Sanjurjo Jose Ramón, Rodríguez Conde Irene, Fernández Soneira María, de la Fuente Aguado Javier
Internal Medicine, Povisa Hospital, Vigo, Spain.
Microbiology, Povisa Hospital, Vigo, Spain.
PLoS One. 2017 May 26;12(5):e0178178. doi: 10.1371/journal.pone.0178178. eCollection 2017.
The aim of this study was to analyze the mortality and predictors of 30-day mortality among hospitalized patients with Pseudomonas aeruginosa urinary tract infection (PAUTI) and the impact of antibiotic treatment on survival.
Patients admitted to our hospital with PAUTI or those diagnosed of PAUTI during hospitalization for other disease between September 2012 and September 2014 were included. Repeated episodes from the same patient were excluded. Database with demographic, clinical and laboratory ítems was created. Empirical and definitive antibiotic therapy, antimicrobial resistance and all-cause mortality at 30 and 90 days were included.
62 patients were included, with a mean age of 75 years. 51% were male. Mortality was 17.7% at 30 days and 33.9% at 90 days. Factors associated with reduced survival at 30 days were chronic liver disease with portal hypertension (P<0,01), diabetes mellitus (P = 0,04) chronic renal failure (P = 0,02), severe sepsis or septic shock (P<0,01), Charlson index > 3 (P = 0.02) and inadequated definitive antibiotic treatment (P<0,01). Independent risk factors for mortality in multivariate analysis were advanced chronic liver disease (HR 77,4; P<0,01), diabetes mellitus (HR 3,6; P = 0,04), chronic renal failure (HR 4,1; P = 0,03) and inadequated definitive antimicrobial treatment (HR 6,8; P = 0,01).
PAUTI are associated with high mortality in hospitalized patients, which increases significantly in those with severe comorbidity such as chronic renal failure, advanced liver disease or diabetes mellitus. Inadequated antibiotic treatment is associated with poor outcome, which remarks the importance of adjusting empirical antibiotic treatment based on the microbiological susceptibility results.
本研究旨在分析铜绿假单胞菌尿路感染(PAUTI)住院患者的死亡率及30天死亡率的预测因素,以及抗生素治疗对生存的影响。
纳入2012年9月至2014年9月期间因PAUTI入院或在因其他疾病住院期间被诊断为PAUTI的患者。排除同一患者的反复发病情例。创建包含人口统计学、临床和实验室项目的数据库。纳入经验性和确定性抗生素治疗、抗菌药物耐药性以及30天和90天的全因死亡率。
共纳入62例患者,平均年龄75岁。51%为男性。30天死亡率为17.7%,90天死亡率为33.9%。与30天生存率降低相关的因素包括伴有门静脉高压的慢性肝病(P<0.01)、糖尿病(P = 0.04)、慢性肾衰竭(P = 0.02)、严重脓毒症或脓毒性休克(P<0.01)、查尔森指数>3(P = 0.02)以及确定性抗生素治疗不充分(P<0.01)。多变量分析中死亡的独立危险因素为晚期慢性肝病(HR 77.4;P<0.01)、糖尿病(HR 3.6;P = 0.04)、慢性肾衰竭(HR 4.1;P = 0.03)以及确定性抗菌治疗不充分(HR 6.8;P = 0.01)。
PAUTI与住院患者的高死亡率相关,在伴有慢性肾衰竭、晚期肝病或糖尿病等严重合并症的患者中死亡率显著增加。抗生素治疗不充分与不良预后相关,这凸显了根据微生物药敏结果调整经验性抗生素治疗的重要性。